Antineoplasic activity of Copaifera multijuga oil and fractions against ascitic and solid Ehrlich tumor.
The aim of this study was to investigate the effect of chronic treatment with C. multijuga oil on Ehrlich tumor evolution. C. multijuga was fractionated in a KOH impregnated silica gel column chromatography to give three distinct fractions, i.e., hexanic, chloroformic, and methanolic, mainly composed by hydrocarbon sesquiterpenes, oxygenated sesquiterpenes and acidic diterpenes, respectively. Results demonstrated that the C. multijuga oil, the hexanic, and chloroformic fractions did not develop toxic effects. The oil, hexanic and chloroformic fractions (doses varying between 100 and 200mg/kg) showed antineoplasic properties against Ehrlich ascitic tumor (EAT) and solid tumor during 10 consecutive days of treatment inhibiting ascitic tumor cell number, reverting medulla and blood cell counts to values similar to control group, and inhibiting the increase on several inflammatory mediators (total protein, PGE(2), nitric oxide, and TNF) on ascitic fluid. The treatment also inhibited the increase in paw volume on tumor-inoculated mice. In conclusion, C. multijuga as well as its fractions demonstrated antineoplasic effect even after oral administration confirming its use by traditional medicine.
Gomes
Niele de Matos
Nde M
Programa de Desenvolvimento de Fármacos, ICB, Universidade Federal do Rio de Janeiro, Caixa Postal 68016, CEP 21944-970, Brazil.
Rezende
Claudia de Moraes
Cde M
Fontes
Silvia Paredes
SP
Hovell
Ana Maria Celestino
AM
Landgraf
Richardt Gama
RG
Matheus
Maria Eline
ME
Pinto
Angelo da Cunha
Ada C
Fernandes
Patricia Dias
PD
D000284:Administration, Oral; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D001202:Ascitic Fluid / Q000187:drug effects / Q000378:metabolism; D001772:Blood Cell Count; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D007887:Fabaceae / Q000737:chemistry*; D018836:Inflammation Mediators / Q000378:metabolism; D008297:Male; D051379:Mice; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology*; D010938:Plant Oils / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D000972:Antineoplastic Agents, Phytogenic; D018836:Inflammation Mediators; D010936:Plant Extracts; D010938:Plant Oils